Preoperatively administered ramosetron oral disintegrating tablets for preventing nausea and vomiting associated with patient-controlled analgesia in breast cancer patients

European Journal of Anaesthesiology

Volumn 25, Issue 9, 2008, Pages 756-762

  Lee, H J ^a   Kwon, J Y ^a,b   Shin, S W ^a   Kim, C H ^a   Baek, S H ^a   Baik, S W ^a   Kim, H K ^a   Kim, K H ^a  

^a Pusan National University   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

Author keywords

Breast surgery; Oral administration; Postoperative nausea and vomiting; Premedication; Ramosetron

Indexed keywords

NITROUS OXIDE; RAMOSETRON; ROCURONIUM; SEVOFLURANE; SODIUM CHLORIDE; THIOPENTAL;

ADULT; ANALGESIA; ARTICLE; BREAST CANCER; CANCER SURGERY; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; ELECTIVE SURGERY; FEMALE; HEADACHE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PAIN ASSESSMENT; PATIENT SATISFACTION; POSTOPERATIVE NAUSEA AND VOMITING; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; ANALGESIA, PATIENT-CONTROLLED; ANALGESICS, OPIOID; ANTIEMETICS; BENZIMIDAZOLES; BREAST NEOPLASMS; FEMALE; FENTANYL; HUMANS; MIDDLE AGED; PAIN MEASUREMENT; PATIENT SATISFACTION; POSTOPERATIVE NAUSEA AND VOMITING; PREMEDICATION; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 49149108086     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1017/S0265021508004262     Document Type: Article

References (36)

1. Cohen MM, Duncan PG, DeBoer DP et al. The postoperative interview: assessing risk factors for nausea and vomiting. Anesth Analg 1994; 78: 7-16.
2. Gan TJ, Ginsberg B, Grant AP et al. Double-blind, randomized comparison of ondansetron and intraoperative propofol to prevent postoperative nausea and vomiting. Anesthesiology 1996; 85: 1036-1042.
3. Sadhasivam S, Saxena A, Kathirvel S et al. The safety and efficacy of prophylactic ondansetron in patients undergoing modified radical mastectomy. Anesth Analg 1999; 89: 1340-1345.
4. White LA, Vanarase M, Brockbank K et al. Patient-controlled analgesia and postoperative nausea and vomiting: efficacy of a continuous infusion of ondansetron. Anaesthesia 2001; 56: 365-369.
5. Walder AD, Aitkenhead AR. Antiemetic efficacy of metoclopramide when included in a patient-controlled analgesia infusion. Anaesthesia 1994; 49: 804-806.
6. Alexander R, Lovell AT, Seingry D et al. Comparison of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient-controlled analgesia. Anaesthesia 1995; 50: 1086-1088.
7. Dresner M, Dean S, Lumb A et al. High-dose ondansetron regimen vs droperidol for morphine patient-controlled analgesia. Br J Anaesth 1998; 81: 384-386.
8. Gombar S, Kaur J, Kumar Gombar K et al. Superior antiemetic efficacy of granisetron-dexamethasone combination in children undergoing middle ear surgery. Acta Anaesthesiol Scand 2007; 51: 621-624.
9. Paech MJ, Rucklidge MW, Lain J et al. Ondansetron and dexamethasone dose combinations for prophylaxis against postoperative nausea and vomiting. Anesth Analg 2007; 104: 808-814.
10. Hartsell T, Long D, Kirsch JR. The efficacy of postoperative ondansetron (Zofran) orally disintegrating tablets for preventing nausea and vomiting after acoustic neuroma surgery. Anesth Analg 2005; 101: 1492-1496.
11. Cohen IT, Joffe D, Hummer K et al. Ondansetron oral disintegrating tablets: acceptability and efficacy in children undergoing adenotonsillectomy. Anesth Analg 2005; 101: 59-63.
12. Fujii Y, Tanaka H, Kawasaki T. Preoperative oral granisetron for the prevention of postoperative nausea and vomiting after breast surgery. Eur J Surg 2001; 167: 184-187.
13. Jokela R, Koivuranta M, Kangas-Saarela T et al. Oral ondansetron, tropisetron or metoclopramide to prevent postoperative nausea and vomiting: a comparison in high-risk patients undergoing thyroid or parathyroid surgery. Acta Anaesthesiol Scand 2002; 46: 519-524.
14. Hirata T, Keto Y, Funatsu T et al. Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. J Pharmacol Sci 2007; 104: 263-273.
15. Noda K, Ikeda M, Yoshida O et al. Clinical evaluation of ramosetron injections in the treatment of cisplatin-induced nausea and vomiting. J Int Med Res 2002; 30: 211-219.
16. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ 1995; 310: 170.
17. Cohen J. A Power Primer. Psychol Bull 1992; 112: 155-159.
18. Reihner E, Grunditz R, Giesecke K et al. Postoperative nausea and vomiting after breast surgery: efficacy of prophylactic ondansetron and droperidol in a randomized placebo-controlled study. Eur J Anaesthesiol 2000; 17: 197-203.
19. Apfel CC, Laara E, Koivuranta M et al. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999; 91: 693-700.
20. Tramer MR. Clinical pharmacology : postoperative nausea and vomiting. Anaesthesist 2007; 56: 679-685.
21. 14C-Ramosetron hydrochloride to rats. Drug Metab Pharmacokinet 1995; 10: 808-818 (in Japanese).
22. Fu Y, Yang S, Jeong SH et al. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst 2004; 21: 433-476.
23. Tang J, Wang B, White PF et al. The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting. Anesth Analg 1998; 86: 274-282.
24. Wang JJ, Ho ST, Tzeng JI et al. The effect of timing of dexamethasone administration on its efficacy as a prophylactic antiemetic for postoperative nausea and vomiting. Anesth Analg 2000; 91: 136-139.
25. Sun R, Klein KW, White PF. The effect of timing of ondansetron administration in outpatients undergoing otolaryngologic surgery. Anesth Analg 1997; 84: 331-336.
26. Fujii Y, Saitoh Y, Tanaka H et al. Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery. Anesth Analg 2000; 90: 472-475.
27. Fujii Y, Tanaka H, Ito M. Ramosetron compared with granisetron for the prevention of vomiting following strabismus surgery in children. Br J Ophthalmol 2001; 85: 670-672.
28. Fujii Y, Tanaka H, Kawasaki T. Benefits and risks of granisetron versus ramosetron for nausea and vomiting after breast surgery: a randomized, double-blinded, placebo-controlled trial. Am J Ther 2004; 11: 278-282.
29. Fujii Y, Uemura A, Tanaka H. Prophylaxis of nausea and vomiting after laparoscopic cholecystectomy with ramosetron: randomised controlled trial. Eur J Surg 2002; 168: 583-586.
30. Tantipalakorn C, Srisomboon J, Thienthong H et al. Comparison of oral versus intravenous ramosetron in prevention of acute cisplatin-induced emesis: a randomized controlled trial. J Med Assoc Thai 2004; 87: 119-125.
31. Kazemi-Kjellberg F, Henzi I, Tramer MR. Treatment of established postoperative nausea and vomiting: a quantitative systematic review. BMC Anesthesiol 2001; 1: 2.
32. Hirata T, Funatsu T, Keto Y et al. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS. Inflammopharmacology 2007; 15: 5-9.
33. Hirata T, Funatsu T, Keto Y et al. Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents. J Pharmacol Sci 2008; 106: 264-270.
34. Bauer KP, Dom PM, Ramirez AM et al. Preoperative intravenous midazolam: benefits beyond anxiolysis. J Clin Anesth 2004; 16: 177-183.
35. Sanjay OP, Tauro DI. Midazolam: an effective antiemetic after cardiac surgery - a clinical trial. Anesth Analg 2004; 99: 339-343.
36. Fujii Y, Tanaka H. Randomized, double-blind, placebo-controlled, dosed-finding study of the antiemetic effects and tolerability of ramosetron in adults undergoing middle ear surgery. Clin Ther 2003; 25: 3100-3108.